Enoxaparin (Lovenox)

Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed)

Also Known As:

Networked: 1907 relevant articles (278 outcomes, 618 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Cohen, Marc: 40 articles (10/2015 - 01/2002)
2.	Antman, Elliott M: 38 articles (12/2012 - 04/2002)
3.	White, Harvey D: 32 articles (07/2013 - 09/2002)
4.	Turpie, Alexander G G: 30 articles (06/2014 - 01/2002)
5.	Eriksson, Bengt I: 29 articles (01/2015 - 01/2002)
6.	Mahaffey, Kenneth W: 25 articles (07/2013 - 01/2003)
7.	Montalescot, Gilles: 23 articles (10/2015 - 01/2003)
8.	Braunwald, Eugene: 21 articles (07/2013 - 04/2002)
9.	Morrow, David A: 21 articles (09/2010 - 06/2002)
10.	Goodman, Shaun G: 20 articles (02/2012 - 02/2002)

Related Diseases

1.	Hemorrhage 11/01/2013 - "There was less major bleeding with enoxaparin (RR 0.46, 95% CI 0.21 to 1.01, p = 0.050) contributing to the significant improvement of the net clinical benefit (RR 0.46, 95% CI 0.3 to 0.74, p = 0.0002). " 10/12/1999 - "Enoxaparin is superior to UFH for reducing a composite of death and serious cardiac ischemic events during the acute management of UA/NQMI patients without causing a significant increase in the rate of major hemorrhage. " 04/01/2012 - "For patients at higher risk of bleeding, dabigatran 150 mg once daily is as effective as enoxaparin following major orthopaedic surgery and is associated with a favourable bleeding rate." 03/01/2012 - "A QI initiative that eliminated the use of enoxaparin for prophylaxis of VTE in patients with renal impairment resulted in lower rates of major bleeding associated with pharmacologic prophylaxis. " 04/01/2011 - "Bleeding, defined according to STEEPLE (Safety and Efficacy of Enoxaparin in PCI Patients, an International Randomized Evaluation) minor or major criteria, occurred in 6.5% of patients over 3 years. "
2.	Venous Thrombosis (Deep-Vein Thrombosis) 07/15/1994 - "To determine the most effective and safe dose of enoxaparin to prevent deep venous thrombosis in high-risk surgical patients. " 10/22/2005 - "Pentasaccharide, an indirect anti-Xa, has proved effective in curing deep-vein thrombosis and more effective than enoxaparin for prophylactic treatment after orthopedic surgery. " 07/15/1994 - "After surgery, enoxaparin, 40 mg once daily or 30 mg every 12 hours, is more effective than a regimen of 10 mg once daily to prevent deep venous thrombosis in patients having elective hip replacement surgery. " 04/02/1992 - "We conclude that a fixed dose regimen of enoxaparin, started post-operatively, is an effective and safe regimen for reducing the frequency of deep vein thrombosis after major knee surgery." 01/01/1990 - "This study indicates that fixed-dose enoxaparin begun post-operatively is effective and safe for the prevention of deep vein thrombosis in patients undergoing elective hip replacement."
3.	Venous Thromboembolism 12/01/2013 - "Although higher dosing of enoxaparin led to improved anti-Xa levels, this did not equate to a statistical decrease in venous thromboembolism." 05/01/2004 - "In general surgery the efficacy of enoxaparin to prevent venous thromboembolism is similar to UFH but the tolerability is better. " 04/01/2013 - " and enoxaparin were both effective in preventing venous thromboembolism in Japanese patients undergoing elective TKA. " 11/01/2011 - "The Venous Thromboembolism Prevention Study has shown that enoxaparin prophylaxis is a safe and effective way of preventing postoperative venous thromboembolism. " 06/01/2013 - "Enoxaparin is effective and safe in surgical patients to prevent venous thromboembolism."
4.	Myocardial Infarction 12/01/2006 - "A recent meta-analysis of ESSENCE, TIMI 11B trial, INTERACT, A to Z and SYNERGY studies has shown that enoxaparin is more effective than UFH in preventing the combined endpoint of death or myocardial infarction in ACS without ST-segment elevation. " 09/29/2009 - "The ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study, a large, randomized, multinational trial, demonstrated a reduction in death or nonfatal myocardial infarction when enoxaparin was used instead of UFH as adjunctive therapy for fibrinolysis in patients with STEMI. " 09/29/2009 - "Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study." 01/01/2009 - "The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction (ExTRACT)-Thrombolysis in Myocardial Infarction (TIMI) 25 trial prospectively studied the usefulness of enoxaparin and found that in patients treated with fibrinolysis, enoxaparin administered throughout the index hospitalization was superior to the standard 48-h UFH infusion. " 09/01/2007 - "A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study."
5.	Thrombosis (Thrombus) 02/01/1988 - "These results suggest that an optimal dosage of 20 mg/day of Enoxaparine is safe and effective in the prevention of postoperative thrombosis in this population." 01/01/1991 - "Second trial, coordinated by S Haas in 1988 on more than 8000 patients confirmed safety and efficacy of enoxaparin in prevention of post-operative thrombosis. " 01/01/2010 - "Improved patency ofdeep veins one month after initiation of treatment was observed in the both groups, however efficacy of enoxaparin turned out to be superior to that of the standard therapy in relation to a decreased number of occlusive thrombosis of veins - 9 versus 41 (p=0.005). " 09/01/2007 - "No adverse effects were associated with antifactor Xa levels greater than 1.0 U/ml. Enoxaparin may be effective in the treatment of neonatal thrombosis. " 10/01/2015 - "Whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates."

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
3.	rivaroxaban
4.	fondaparinux (Arixtra)
5.	Dalteparin (Dalteparin Sodium)
6.	Aspirin (Acetylsalicylic Acid)
7.	Warfarin (Coumadin)
8.	Enoxaparin (Lovenox)
9.	apixaban
10.	Factor Xa (Coagulation Factor Xa)

Related Therapies and Procedures

1.	Arthroplasty
2.	Hip Replacement Arthroplasty (Total Hip Replacement)
3.	Knee Replacement Arthroplasty (Total Knee Replacement)
4.	Angioplasty (Angioplasty, Transluminal)
5.	Stents